Press release | 9th February 2016
Octapharma Selects IDBS’ E-WorkBook 10
Web deployment will see leading biotech replace paper and protect IP
Boston, US & London, UK, February 9, 2016 – Octapharma GmbH (‘Octapharma’), a leading biopharmaceuticals organization, has chosen E-WorkBook 10 from IDBS. The web-based electronic laboratory notebook (ELN) will be rolled out in Germany early this year to replace paper-based research and development (R&D) and protect valuable IP. Users will be able to search for information in real time and follow a specific researcher or experiment as part of the application, to boost collaboration and productivity.
Christoph Kannicht, Senior Director, Scientific Services R&D at Octapharma said, “We’ve been working on paper for many years and it became clear that we needed to standardize the way we capture and share data to compete effectively in today’s marketplace.
Initially we will do away with paper notebooks in the lab and standardize the way we collect and store data using E-WorkBook 10, so that our scientists can share information quickly and effectively. Over the long term, the platform will grow with us and afford us the benefits of streamlining our workflow and processes without having to change tools.”
E-WorkBook 10 will service the breadth of expertise across Octapharma’s German labs, including High Throughput Screening (HTS), fermentation, analytics and formulations. Increasingly, it will also help the organization to collect and secure data from its biotech partnerships. The transition from legacy technology and Excel is already underway, supported by IDBS’ Munich team on the ground.
“The need to work faster and smarter in R&D has never been more apparent, as labs are increasingly partnering with contract research organizations (CROs) and innovative biotechs to deliver results,” said J.T Kaminski, Director of Technology Services, DACH, IDBS. “With E-WorkBook 10, Octapharma is using cutting-edge technology and the internet to facilitate data capture and protection within its organization. This ‘lab of the future’ approach will see it capture ideas and concepts now, with a view to grow, supported by our German team in local language.”
The web-based deployment of E-WorkBook 10 delivers Octapharma a small IT footprint throughout the organization – compared to an on-premise solution – and a mobile approach to R&D. Scientists can access data from anywhere in the world with just a connection to the internet and their internal system.
Headquartered in Lachen, Switzerland, Octapharma is one of the largest human protein product manufacturers in the world and has been committed to patient care and medical innovation since 1983. Its core business is the development and production of human proteins from human plasma and human cell-lines.
Octapharma has 48 subsidiaries and representative offices and employs approximately 6,000 people worldwide to support the treatment of patients in over 100 countries with products across the therapeutic areas of Haematology (coagulation disorders), Immunotherapy (immune disorders) and Critical Care.
Octapharma owns five state-of-the-art production facilities in Austria, France, Germany, Sweden and Mexico.
For more information visit www.octapharma.com
IDBS is a leading global provider of advanced software for research and development (R&D) organizations to securely capture, manage, share and exploit structured and unstructured data. Our technology and domain expertise enable users to link data to data, data to people and people to people to drive innovation, achieve faster time to market and improve margins. Our diverse customer list includes R&D driven international companies in pharmaceuticals, biotechnology, agricultural sciences, chemicals, consumer goods, energy, engineering, food and beverage, and healthcare.
Founded in 1989, IDBS is headquartered in the United Kingdom with offices across Europe, Asia and the United States. IDBS remains a privately held company employing over 250 staff across the world and serving over 50,000 researchers in 25 countries – including over 80% of the top twenty pharmaceutical companies.